Literature DB >> 18504699

Polycystic ovary syndrome: the controversy of diagnosis by ultrasound.

Misty Blanchette Porter1.   

Abstract

Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder. The criteria used to establish the diagnosis remain controversial. The 1990 National Institutes of Health conference guidelines required a combination of both chronic anovulation and clinical/or biochemical signs of hyperandrogenism. These criteria were revised in 2003 at the Rotterdam European Society of Human Reproduction and Embryology/American Society of Reproductive Medicine consensus workshop to include ultrasound polycystic ovarian morphology (PCOM) as one of the two of three criteria necessary for establishing the diagnosis of PCOS. The inclusion of PCOM sparked a controversy as it broadens the population of women who meet the criteria for PCOS and allows for the creation of two phenotypically different patient populations who previously would have been excluded. The ultrasound findings, which are consistent with PCOM, include an assessment of follicle number and/or ovarian volume. As technology advances with two-dimensional and three-dimensional ultrasound, our ability to discretely evaluate independent portions of the ovary may help to redefine the criteria of PCOM and thus standardize for clinical and research interests a more specific descriptor for PCOM.

Entities:  

Mesh:

Year:  2008        PMID: 18504699     DOI: 10.1055/s-2008-1076143

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  2 in total

1.  Laparoscopic uteroovarian ligament truncation and uterosacral oophoropexy for idiopathic recurrent ovarian torsion: case report and review of literature.

Authors:  Paula C Brady; Aaron K Styer
Journal:  Fertil Res Pract       Date:  2015-04-21

2.  Comparison of image features and diagnostic value of color Doppler ultrasound and two-dimensional ultrasound in the diagnosis of ovarian sex cord-stromal tumors.

Authors:  Guannan He; Jing Zhao; Zhirong Yang; Zhigang Zhao; Yan Bai; Wen Xiong
Journal:  Oncol Lett       Date:  2020-06-05       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.